Mr. Beaver's practice focuses on the representation of manufacturers whose products and activities are regulated by the Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), and the Federal Trade Commission (FTC), with special emphasis on compliance with federal regulatory requirements for developing, manufacturing and marketing FDA-related products. He also advises clients on regulatory issues affecting prescription and over-the-counter drug products (including animal drugs), medical devices, dietary supplements, cosmetics, and foods with special emphasis on the regulatory structure for drug products including approval process and patent and exclusivity issues related to the Hatch-Waxman Act.

Prior to joining Foley, Mr. Beaver was an associate at DLA Piper Rudnick Gray Cary, and at McDermott, Will & Emery.

Mr. Beaver earned his J.D. from Georgetown University Law Center in 1997. He graduated cum laude in 1994 from the University of Arizona with a Bachelor of Arts degree in interdisciplinary studies.

Mr. Beaver also has significant experience litigating FDA and Hatch-Waxman cases involving drug approvals, withdrawals and other types of litigation involving FDA regulated products.

Mr. Beaver is admitted to practice in the District of Columbia.